echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System >  Eur J Neurol.: Visual spatial dysfunction is related to the posterior distribution of white matter damage in non-dementia cerebral amyloid angiopathy

     Eur J Neurol.: Visual spatial dysfunction is related to the posterior distribution of white matter damage in non-dementia cerebral amyloid angiopathy

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral amyloid angiopathy (CAA) is characterized by the deposition of β-amyloid (Aβ) in the small arteries of the cortex and pia mater, which is the most common and severe posterior brain area
    .


    A large number of studies have shown that CAA is a recognized determinant of vascular cognitive impairment and Alzheimer’s disease dementia in the elderly, and it is dependent or independent of cerebral hemorrhage (ICH) events


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.